Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Recruitment Information:

Seeking volunteers with following diagnosis: PD Study Type: Interventional
Eligible Ages: 18 - 79 Status: Recruiting
Time Since Diagnosis: Any may be eligible Study Focus:

Study Purpose:

IRL790 is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term levodopa treatment in patients with Parkinson's disease. In experimental animals IRL790 potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian effect of levodopa. The primary purpose of the trial is to investigate whether IRL790 given as adjunctive treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The trial will also help to establish the most optimal dosing of the compound.

Find a Site Location and Contact the Trial Team

More Details

Phase: Phase 2 Lead Sponsor: Integrative Research Laboratories AB
Trial ID: 005135 Sponsor Type: Industry
Primary Country: United States Additional Collaborators or Sponsors: The Clinical Trial Company
Estimated Enrollment: 74 Study Start Date: February 2018
Estimated Study Completion Date: December 2018 Source: ClinicalTrials.gov
Study Website:

More Inclusion & Exclusion Criteria

Share This Trial

Fox Trial Finder strives to make all trial postings as accurate and complete as possible. If you believe any of the information on this page is not accurate, click here to contact us. Thank you for your support.

Choose your location

Please select a Trial Location.


You have favorited this trial!

This trial will be listed in the "Favorites" category of your dashboard.


You are not interested.

This trial will be listed in the "Not Interested" category on your dashboard. You can click "Interested" if you change your mind.

Message to Trial Coordinator

Your message was sent.

Your message was sent to the trial team at the location you selected. Check your dashboard for a response.

Login to My Trial Finder

Please enter your email address and password to access your My Fox Trial Finder dashboard.

*indicates required field.

Contact Fox Trial Finder

What best describes you?

*indicates required field.